Updates
What's new
Content additions, new features, and corrections — updated regularly so you can follow what has changed on WhatIsLCA.
- Content
EMA orphan designation for the LCA1 gene therapy
- The LCA1 (GUCY2D) page and timeline now note that the European Medicines Agency granted orphan designation to Atsena's ATSN-101 in July 2026, ahead of a global pivotal Phase 3 planned across the US, Europe and Japan.
- Content
A faster FDA path for the LCA5 gene therapy
- The LCA5 page and timeline now cover Opus Genetics' July 2026 FDA alignment on a streamlined Phase 3 for OPGx-LCA5: participants serve as their own control after a six-month run-in, the primary endpoint is a ≥7 dB gain in retinal sensitivity, and a marketing application may be filed on six-month data (with RMAT designation opening an accelerated route).
- The “From Lab to Patient” page gained a short explainer on how the development journey can be made faster for ultra-rare diseases, using this alignment as a real example.
See what changed - New
“From Lab to Patient” — how a gene therapy is developed
- A new page maps the whole journey from discovery to an approved treatment — animal studies, IND-enabling work, human trials, and regulatory review — as an easy-to-follow roadmap.
- It also shows the tracks that run in parallel (funding, FDA designations, manufacturing, and patient recruitment), plus a plain-language walkthrough of how patients actually join a trial.
See what changed - Content
RPGRIP1 (LCA6) gene-therapy program and its evidence
- The LCA6 (RPGRIP1) type page now covers Odylia Therapeutics' OT-004 — an AAV (Anc80) gene-augmentation therapy in late-stage preclinical development, with FDA Orphan Drug and Rare Pediatric Disease designations and no clinical trial registered yet.
- Added the academic proof-of-concept behind it: photoreceptor rescue in RPGRIP1-knockout mice (Pawlyk 2005/2010) and durable cone-vision rescue in the RPGRIP1-deficient dog (Lhériteau 2014), plus a 228-patient natural-history reference (Beryozkin 2021).
- Three RPGRIP1 milestones added to the timeline (2005 mouse, 2014 dog, 2021 FDA designations).
See what changed - Content
Preclinical and early-trial status added for 11 more LCA genes
- Reviewed every remaining LCA type for gene-therapy activity and added the peer-reviewed evidence behind it: academic proof-of-concept in animal or organoid models for SPATA7 (LCA3), CRX (LCA7), NMNAT1 (LCA9), RD3 (LCA12), TULP1 (LCA15), KCNJ13 (LCA16), IQCB1/NPHP5, IFT140, and CABP4.
- Documented the two with human data: LRAT (LCA14), an oral-retinoid Phase 1b that later stalled, and PRPH2 (LCA18), an individualized single-patient antisense trial — each described honestly with its limits.
- Genes with no gene-therapy proof yet (IMPDH1, GDF6, USP45, CCT2, CLUAP1, DTHD1, OTX2) were deliberately left unchanged — no claim without a citation.
- The nine animal/organoid proof-of-concept studies were also plotted on the timeline (2013–2026), showing how gene-therapy research now spans many LCA genes.
See what changed - Content
Added a 2026 Lancet review as an overview reference
- The “How Treatments Work” page now cites a peer-reviewed Lancet review (2026) of inherited retinal degenerations and their emerging gene, cell, optogenetic, and implant therapies — an authoritative overview covering all the approaches described.
See what changed - Improved
Treatment diagrams now play automatically
- On the “How Treatments Work” page, each mechanism’s steps advance on their own with a progress bar — and pause the moment you click, so you can explore at your own pace.
See what changed - New
Report an error on any page, and an editorial-standards page
- Every page now has a one-click way to report an inaccuracy — via a form (no account needed) or our public community repository.
- A new “Editorial standards” page explains how we source, review, and keep content current.
- Pages now show a medical-review status so you can see how thoroughly each has been checked.
See what changed - New
“How Treatments Work” — an interactive 3D explainer
- A new page walks through gene augmentation, gene editing (CRISPR), RNA therapy, stem-cell therapy, and optogenetics with step-by-step 3D visuals and a plain-language comparison.
See what changed
Spotted something out of date? Use the report button in the footer of any page.